Therapeutic Goods (Charges) Amendment Bill 2026; Second Reading

Summary

The Therapeutic Goods Administration charges system gets updated to adjust how much companies pay when they register medicines, medical devices, and other therapeutic products. This amends the Therapeutic Goods Act 1989 by changing the fee structure that drug and device makers must pay to have their products approved and listed on the Australian Register of Therapeutic Goods. The change matters because it affects the cost of doing business for pharmaceutical and medical device companies, which can ultimately influence medicine prices, competition in the market, and how quickly new treatments become available to Australian patients.

What happens at this stage

The main debate on whether the chamber supports the broad purpose of the bill. Members speak to its overall merits and concerns rather than the fine print. The government outlines its policy intentions; the opposition and crossbench put their case. This is the stage that determines whether the bill proceeds at all.

Next: Consideration in Detail (House) or Committee of the Whole (Senate), where the bill is examined clause by clause